Special Issue

Precision Medicine for Hematological Malignancies

Message from the Guest Editors

The field of malignant hematology has been on the precipice of advancements in precision medicine. This Special Issue highlights cutting-edge research and clinical advances in myeloid malignancies, lymphoid neoplasms, plasma cell dyscrasias, and hematopoietic stem cell transplantation. The scope of topics in this Special Issue includes genomic profiling, targeted therapies, biomarker-driven treatment approaches, and novel immune targets and immunotherapeutic agents, as well as studies evaluating novel risk stratification and prognostic factors. Original research papers are encouraged; however, meta-analyses and topic reviews will also be considered for publication.

Guest Editors

Dr. Anthony M. Hunter

Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory University, Atlanta, GA, USA

Dr. Jason Romancik

Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory University, Atlanta, GA, USA

Deadline for manuscript submissions

closed (30 June 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/185382

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpl.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

